Ocular Therapeutix Inc. (NASDAQ: OCUL ) stock is trading higher on Monday as the stock reacts to underwhelming data from its rival, EyePoint Inc. (NASDAQ: EYPT ).
EyePoint released topline results from its pivotal Phase 3 LUGANO trial. The study evaluated Duravyu for wet age-related macular degeneration, or wet AMD .
The trial showed significant clinical progress on key secondary endpoints. However, it failed to meet its primary visual acuity endpoint. EyePoint attributed the result to a confounding patient subgroup .
Ocular Therapeutix Advances Axpaxli For Wet AMD
Ocular Therapeutix is developing Axpaxli, also known as OTX-TKI, for wet AMD and diabetic retinal disease. The investigational treatment combines a bioresorbable intravitreal hydrogel with axitinib. Axitinib is a small-molecule, multi-target tyrosine kinase inhibitor.
The company is planning to submit a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2026 .
The company will support the application with SOL-1 efficacy and safety data. It will also include an interim SOL-R safety analysis of patients who reach Week 52 in the fourth quarter, along with confirmatory evidence.
In its latest quarterly earnings release, Peter Kaiser, Chief Development Officer of Ocular Therapeutix, said, “SOL-1 is the first and only successful superiority trial of a novel agent against an approved anti-VEGF therapy since the class emerged two decades ago .”
Read Next NewsOcular's Axpaxli Cuts Risk Of Worsening In Late-Stage AMD Study
Ocular Therapeutix shares up on positive data for wet AMD treatment. Company focusing on retinal diseases and on track for FDA submission.
2 min read Read this articleAnalyst Says EyePoint Data Validate Axpaxli Profile
William Blair on Monday wrote, “Given the totality of the data here, we expect Duravyu would likely be able to be filed on a clean positive readout from LUCIA, though we see greater regulatory risk.”
Latest Private Market Opportunities Join 400,000+ InvestorsAnalyst Lachlan Hanbury-Brown said the results provide additional validation for the TKI class . However, he said differences in trial design make a direct comparison between Duravyu and Axpaxli difficult.
William Blair also said the positive topline and additional SOL-1 results support Axpaxli’s profile as a durable and effective treatment for nAMD. The firm sees potential in other vascular retinal diseases as well.
The firm said the results also reduce risk around the ongoing SOL-R study, which is expected to read out in the first quarter of 2028, as well as Axpaxli’s potential approval.
OCUL Stock Price Activity: Ocular Therapeutix shares were up 6.32% at $10.81 at the time of publication on Monday, according to Benzinga Pro data .
Image via Shutterstock
Read Next Analyst RatingsJetBlue 'Worthless'? Analyst Cuts Rating As Us-Iran Conflict Keeps Jet Fuel Volatile
JetBlue may increase its debt to fund losses, leading to its shares ultimately becoming “worthless,” one analyst said.
2 min read Read this article Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here .
Posted In: Trading Ideas Movers News Analyst Ratings Analyst Color General Biotech Top Stories Health Care Why It's Moving Expert Ideas